DCAT Week 2025: Quality and Compliance for Animal-derived Products

News
Video

Pharmaceutical Technology® discusses the quality and compliance issues surrounding the use of animal-derived ingredients in the bio/pharma industry with Roger Viney, chief commercial officer of ICE Pharma.

“There are two main differences in terms of quality and compliance that you have to take into account when you're handling animal-derived products,” explains Roger Viney, chief commercial officer of ICE Pharma. “The first is to have steps in your process that ensure biological inactivation, whether it's of course, removal of bacteria, denaturing of DNA, and particularly viral inactivation.”

Secondly, Viney adds that traceability is important: Knowing the exact origin of the animal-derived material means that should there be any issues in a particular country or with a particular disease, it is easy to identify and segregate the material that will be affected, he remarks.

Looking at regulatory requirements, Viney points out that harmonization is critical and allows for increased security of supply. Furthermore, offering fully integrated services is an added benefit for customers as it provides them with the confidence in traceability of the products, he specifies.

Click above to watch the full interview

In December 2024, Pharmaceutical Technology® spoke with Viney about the utility of bile acids as excipients to help improve solubility and bioavailability. The interview can be viewed by following the link below:

https://www.pharmtech.com/view/improving-solubility-and-bioavailability-with-bile-acids

About the speaker

Roger Viney, PhD, is the chief commercial officer for ICE Pharma and is responsible for the global commercial functions. Roger has a 30-year career, starting in R&D and then moving across to sales, marketing, key account management, and business and product management for the pharma market.

Recent Videos
Tore Bergsteiner from MAIN5 discusses the most pertinent and impactful bio/pharma industry trends from 2024.
Simon Wright from Almac Pharma Services chats about shifting demand for commercial manufacturing services and how service providers are adapting to meet demand.
Ian Lafferty from Upperton discusses the trends and challenges facing sterile manufacturing and how partnering with CDMOs can help innovators progress to the market.
Miguel Forte from ISCT and Kiji Therapeutics talks about the potential impact of a changing European political landscape.
Miguel Forte from ISCT and Kiji Therapeutics provides his insights into the changing political landscape in the US as well as legislative and regulatory adjustments
Miguel Forte from ISCT and Kiji Therapeutics chats about expectations for 2025 and the future technology agenda for industry.
Sheryl Johnson from Orbia Fluor & Energy Materials chats about gender diversity, how women are helping to advance innovation, sustainability challenges, and progress in the field of inhaled drugs.